CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $2.75B, above the global median of $1.14B
- FinancialsAltman Z-Score 6.73: safe zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.06BGBP2.75B · vs all stocks (USD)
Revenue (TTM)
235.00MGBP314.34M · vs all stocks (USD)
Profit Margin
-51.66%vs Biotechnology peers
Beta
0.8710xvs all stocks
52-Week Change
52.24%vs all stocks
Forward Annual Dividend Yield
0.00%vs all stocks
Market Capitalization
2.06BGBP2.75B · vs all stocks (USD)
Enterprise Value
1.91BGBP2.55B · vs all stocks (USD)
Forward P/E
-29.06xvs Biotechnology peers
Price to Sales (TTM)
8.76xvs Biotechnology peers
Price to Book (MRQ)
4.84xvs Biotechnology peers
Enterprise to Revenue
8.12xvs Biotechnology peers
Enterprise to EBITDA
-20.66xvs Biotechnology peers
Profit Margin
-51.66%vs Biotechnology peers
Operating Margin
-43.45%vs Biotechnology peers
Return on Assets (TTM)
-10.94%vs Biotechnology peers
Return on Equity (TTM)
-25.62%vs Biotechnology peers
Revenue (TTM)
235.00MGBP314.34M · vs all stocks (USD)
Revenue per Share (TTM)
0.2430GBPUpdated Oct 25, 2026Quarterly Revenue Growth
10.50%vs Biotechnology peers
Gross Profit (TTM)
147.60MGBP197.43M · vs all stocks (USD)
EBITDA (TTM)
-92.40MGBP-123.60M · vs all stocks (USD)
Net Income (TTM)
-121.40MGBP-162.39M · vs all stocks (USD)
Operating Cash Flow (TTM)
-65.00MGBP-86.94M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-49.70MGBP-66.48M · vs all stocks (USD)
Forward Annual Dividend Yield
0.00%vs all stocks
Trailing Annual Dividend Rate
0.00GBPUpdated Oct 25, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Revenue
223.90MGBPFY2025 · Dec 31, 2025Cost of Goods Sold
92.60MGBPFY2025 · Dec 31, 2025Gross Profit
131.30MGBPFY2025 · Dec 31, 2025Operating Income
-155.30MGBP-207.73M · vs all stocks (USD)
Pre-tax Income
-139.90MGBPFY2025 · Dec 31, 2025Income Tax Expense
5.30MGBPFY2025 · Dec 31, 2025Net Income
-145.20MGBPFY2025 · Dec 31, 2025EBIT
-137.10MGBPFY2025 · Dec 31, 2025EBITDA (Income Statement)
-93.70MGBPFY2025 · Dec 31, 2025Research & Development
97.70MGBPFY2025 · Dec 31, 2025Selling, General & Administrative
188.90MGBPFY2025 · Dec 31, 2025Non-operating Interest Income
11.80MGBPFY2025 · Dec 31, 2025Non-operating Interest Expense
2.80MGBPFY2025 · Dec 31, 2025EPS (Basic)
-0.1510GBPFY2025 · Dec 31, 2025EPS (Diluted)
-0.1510GBPFY2025 · Dec 31, 2025Basic Shares Outstanding
960.99MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
960.99MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-139.90MGBPFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00GBPFY2025 · Dec 31, 2025Operating Cash Flow
-147.30MGBPFY2025 · Dec 31, 2025Free Cash Flow
-150.80MGBPFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
181.10MGBPFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-139.90MGBPFY2025 · Dec 31, 2025Stock-based Compensation
20.40MGBPFY2025 · Dec 31, 2025Other Non-cash Items
-23.30MGBPFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-9.40MGBPFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
4.90MGBPFY2025 · Dec 31, 2025Capital Expenditures
-3.50MGBPFY2025 · Dec 31, 2025Purchase of Investments
-49.90MGBPFY2025 · Dec 31, 2025Sale of Investments
144.10MGBPFY2025 · Dec 31, 2025Net Investing Cash Flow
90.70MGBPFY2025 · Dec 31, 2025Net Financing Cash Flow
6.70MGBPFY2025 · Dec 31, 2025Shares Outstanding
975.25MSharesUpdated Oct 25, 2026Float Shares
464.40MSharesUpdated Oct 25, 2026% Held by Insiders
42.37%vs all stocks
% Held by Institutions
31.93%vs all stocks
Total Cash (MRQ)
184.80MGBP247.19M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.1890GBPUpdated Oct 25, 2026Total Debt (MRQ)
41.80MGBP55.91M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0986xvs Biotechnology peers
Current Ratio (MRQ)
3.52xvs Biotechnology peers
Book Value per Share (MRQ)
0.4350GBPUpdated Oct 25, 2026Total Assets
622.50MGBP832.66M · vs all stocks (USD)
Total Current Assets
420.00MGBPFY2025 · Dec 31, 2025Total Liabilities
159.20MGBPFY2025 · Dec 31, 2025Total Non-current Assets
202.50MGBPFY2025 · Dec 31, 2025Total Non-current Liabilities
41.20MGBPFY2025 · Dec 31, 2025Total Current Liabilities
118.00MGBPFY2025 · Dec 31, 2025Cash & Cash Equivalents
181.10MGBPFY2025 · Dec 31, 2025Other Short-term Investments
74.20MGBPFY2025 · Dec 31, 2025Accounts Receivable
46.50MGBPFY2025 · Dec 31, 2025Inventory
81.50MGBPFY2025 · Dec 31, 2025Accounts Payable
18.40MGBPFY2025 · Dec 31, 2025Short-term Debt
5.20MGBPFY2025 · Dec 31, 2025Other Current Liabilities
-500.00KGBPFY2025 · Dec 31, 2025Long-term Debt
36.30MGBPFY2025 · Dec 31, 2025Other Non-current Liabilities
1.00MGBPFY2025 · Dec 31, 2025Common Stock (Book)
100.00KGBPFY2025 · Dec 31, 2025Retained Earnings
-550.90MGBPFY2025 · Dec 31, 2025Total Shareholders' Equity
463.30MGBP619.71M · vs all stocks (USD)
52-Week Low
95.61GBXUpdated Oct 25, 202652-Week High
238.80GBXUpdated Oct 25, 202652-Week Change
52.24%vs all stocks
Beta
0.8710xvs all stocks
50-Day MA
183.17GBXUpdated Oct 25, 2026200-Day MA
139.40GBXUpdated Oct 25, 2026Avg 10-Day Volume
2.06MSharesUpdated Oct 25, 2026Avg 30-Day Volume
3.37MSharesUpdated Oct 25, 2026Diluted EPS (TTM)
-0.1300GBPUpdated Oct 25, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 6.73: safe zoneNotable
Altman Z-Score: 6.73
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $2.75B, above the global median of $1.14BNotable
Market cap (USD): 2,753,671,791.826Global Median: 1,138,591,906.897
Companies that share the same coordination system — how they create, deliver, or capture value.
Hebei Changshan Biochemical Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Neogen Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
Kangmei Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Guangzhou Innogen Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
China Resources Double Crane Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
GN Store Nord A/S
Tier 1ProductionApproval-Gated PipelineRuleFlow
TransMedics Group Inc.
Tier 1ProductionApproval-Gated PipelineFlowRule
Acro Biosystems Co., Ltd.
Tier 1ProductionApproval-Gated PipelineSenseMakingFlow
Adma Biologics Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Lepu Medical Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow